Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib plus 131I in postoperative recurrent/metastatic differentiated thyroid cancer
ChiCTR2400089560Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib in well-differentiated thyroid cancer (WDTC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective response rate. Started Jul 2024; status: recruiting.
02
Drugs
donafenib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2400089560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089560.